ICICI Prudential Mutual Fund decreased its stake in Cohance Lifesciences from 4.49% to 4.19%, selling 11,44,549 shares worth ₹50.59 crore.
A Hyderabad-based contract development and manufacturing organization serving leading global pharmaceutical and fine chemical companies. Cohance Life provides integrated services spanning process research and development through late-stage clinical and commercial manufacturing for new chemical entities. The company distinguishes itself through its commitment to delivering customized solutions that fulfill specific customer needs and expectations across the entire drug development lifecycle.
India's second-largest AMC by AUM with over Rs 9 lakh crore managed across 80+ schemes. Joint venture between ICICI Bank and Prudential plc. CIO S. Naren is one of India's most recognised value investors, known for contrarian macro calls and rotating across market caps well ahead of consensus. ICICI Pru's quarterly portfolio disclosures are among the most closely watched in the industry.